Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 6/20 | 0.49 |
| ▸ | FBP1 | P09467 | 3/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14517130 | 0.86 | PPARA (0.57) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL17009120 | 0.86 | PPARA (0.49) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL17009152 | 0.84 | PPARA (0.46) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL4111625 | 0.84 | PPARA (0.59) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL17009106 | 0.83 | PPARA (0.53) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL14290524 | 0.83 | PPARA (0.56) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL4117710 | 0.83 | PPARA (0.62) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL4117714 | 0.83 | PPARA (0.58) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL17009142 | 0.82 | ALOX5 (0.56) | CYP1A2CYP3A4ALOX5KMT2A | |
| SCHEMBL14517146 | 0.82 | PPARA (0.54) | PPARAABCB11CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079745-A1 | PYRAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION SCIENCES, INC. | 2018-03-22 | — | — | US | disclosed |
| US-9862708-B2 | Pyrazolone compounds and uses thereof | TEMPEST THERAPEUTICS, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170174666-A1 | PYRAZOLONE COMPOUNDS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| EP-3105205-A1 | PYRAZOLONE COMPOUNDS AND USES THEREOF | Inception 2, Inc. (US) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015123133-A1 | PYRAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2, INC. (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174666-A1 | PYRAZOLONE COMPOUNDS AND USES THEREOF | PPARA, PPARG, PPARD | PPARA 1/4885ABCB11 1296/4885CYP1A2 472/4885 |
| US-20180079745-A1 | PYRAZOLONE COMPOUNDS AND USES THEREOF | PPARA, PPARG, PPARD | PPARA 1/4885ABCB11 1117/4885CYP1A2 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.